Page 13 - Dermavant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dermavant Sciences: Dermavant Announces Appointment of Michael Swartzburg as Chief Financial Officer - Over 20 Years of Combined Experience in Global Finance Leadership, Audit, and Advisory Roles in the Biopharmaceutical Industry - Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the appointment of Michael Swartzburg as Chief Financial Officer. Mr. Swartzburg brings extensive finance expertise, with over 20 years of leadership within the biotechnology and healthcare space. ...

(0) - Approximately One in Five Tapinarof Patients Achieved At Least 90% Disease Clearance - - A Significantly Higher Portion of Psoriasis Patients Experienced Clinically Meaningful Improvements in Itch with Tapinarof Compared to Vehicle - - Improvements in DLQI Exceeded MCID at Week 12 with Statistical Significance Compared to Vehicle - - Data Will Be Included in NDA Submission for Tapinarof, Expected Mid-2021 - Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, will present data from its t...

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021 Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavant's two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), on April 23-25, 2021. Tapinarof is being developed as a novel, once-daily th...

Dermavant Sciences: Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that an abstract containing interim analysis data from Dermavant's PSOARING 3 long-term, open-label safety study for tapinarof for the treatment of psoriasis in adults will be presented in poster format during the upcoming Innovations in Dermatology Virtual Spring Conference 2021, held from March 16-20, 2021. The f...

Psoriasis Pipeline Insight 2021 | Latest Advancements in Clinical Trials to Improve Treatment Psoriasis treatment has expanded dramatically over the past decade, and the growth shows no signs of stopping, as many prominent players such as Abbvie, Jannsen, Dermavant Sciences, UCB, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Arcutis Biotherapeutics, Amgen, Mylan, Clover Biopharmaceuticals, Sienna Biopharmaceuticals, Fresenius Kabi, Celltrion, Bristol Myers Squibb, LEO Pharma, Crescita Therapeutics, GlaxoSmithKline, Coherus BioSciences, Fujifilm Kyowa Kirin Biologics, Zydus Cadilla, S...